{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:12Z","timestamp":1792508232686,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.phrs.2024.107163","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:26:25Z","timestamp":1711985185000},"page":"107163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacological agents targeting drug-tolerant persister cells in cancer"],"prefix":"10.1016","volume":"203","author":[{"given":"Yu-Chi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishne","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantu","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2024.107163_bib1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cancers13051118","article-title":"Fighting drug resistance through the targeting of drug-tolerant persister cells","volume":"13","author":"De Conti","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.phrs.2024.107163_bib2","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1535-7163.MCT-19-0360","article-title":"Development of a novel multi-isoform ALDH inhibitor effective as an antimelanoma agent","volume":"19","author":"Dinavahi","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107163_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104483","article-title":"Redox signaling in drug-tolerant persister cells as an emerging therapeutic target","volume":"89","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib6","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12079-017-0435-1","article-title":"Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance","volume":"12","author":"Hammerlindl","year":"2018","journal-title":"J. Cell Commun. Signal."},{"issue":"5","key":"10.1016\/j.phrs.2024.107163_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.342","article-title":"Targeting drug-tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells","volume":"4","author":"Song","year":"2023","journal-title":"MedComm"},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib9","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib10","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27855","article-title":"Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer","volume":"12","author":"Blagoev","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107163_bib11","article-title":"Immune evasion and drug resistance mediated by USP22 in cancer: novel targets and mechanisms","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2024.107163_bib12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of Cancer Resistance to Immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2024.107163_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.csbj.2020.12.042","article-title":"Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter","volume":"19","author":"Tangella","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"15","key":"10.1016\/j.phrs.2024.107163_bib14","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-11-0221","article-title":"ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients","volume":"71","author":"Wilson","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","article-title":"The role of CD133 in cancer: a concise review","volume":"7","author":"Glumac","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"38","key":"10.1016\/j.phrs.2024.107163_bib16","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.1073\/pnas.0905653106","article-title":"Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment","volume":"106","author":"Bertolini","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2024.107163_bib17","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-10-3997","article-title":"Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth","volume":"71","author":"Civenni","year":"2011","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.phrs.2024.107163_bib18","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"issue":"49","key":"10.1016\/j.phrs.2024.107163_bib19","doi-asserted-by":"crossref","first-page":"81026","DOI":"10.18632\/oncotarget.13186","article-title":"Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT\/beta-catenin pathway.","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2015.30","article-title":"Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib","volume":"1","author":"Lehraiki","year":"2015","journal-title":"Cell Discov."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.31881","article-title":"KDM5 demethylases and their role in cancer cell chemoresistance","volume":"144","author":"Plch","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","article-title":"Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells","volume":"23","author":"Roesch","year":"2013","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib23","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation","volume":"74","author":"Raha","year":"2014","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.phrs.2024.107163_bib24","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/onc.2011.447","article-title":"Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer","volume":"31","author":"Werner","year":"2012","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.phrs.2024.107163_bib25","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/bjc.2017.279","article-title":"Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer","volume":"117","author":"Codony-Servat","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"AXL in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib27","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and error-prone dna replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107163_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673154","article-title":"GLI1: a therapeutic target for cancer","volume":"11","author":"Avery","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70871-9","article-title":"Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells","volume":"10","author":"Po","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13046-018-0917-x","article-title":"GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells","volume":"37","author":"Huang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib31","first-page":"100","article-title":"Gli2 mediates the development of castration\u2011resistant prostate cancer","volume":"57","author":"Xia","year":"2020","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.phrs.2024.107163_bib32","first-page":"57","article-title":"Targeting STK11 mutations in cancer","volume":"11","author":"Holmes","year":"2022","journal-title":"Target. Ther. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107163_bib34","article-title":"Hedgehog-Gli2 signaling promotes chemoresistance in ovarian cancer cells by regulating MDR1","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.phrs.2024.107163_bib35","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1200\/JCO.2018.36.15_suppl.9028","article-title":"Association of STK11\/LKB1 mutations with primary resistance to PD-1\/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC","volume":"36","author":"Skoulidis","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib36","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/onc.2016.348","article-title":"Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells","volume":"36","author":"Fai\u00e3o-Flores","year":"2017","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.phrs.2024.107163_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194746","article-title":"Defining the role of GLI\/hedgehog signaling in chemoresistance: implications in therapeutic approaches","volume":"13","author":"Chai","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"29","key":"10.1016\/j.phrs.2024.107163_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj9138","article-title":"Noncanonical activation of GLI signaling in SOX2(+) cells drives medulloblastoma relapse","volume":"8","author":"Swiderska-Syn","year":"2022","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib39","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1080\/15548627.2015.1091910","article-title":"Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK\/p38","volume":"11","author":"Grossi","year":"2015","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41417-023-00687-y","article-title":"STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines","volume":"31","author":"Lenahan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031058","article-title":"Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation","volume":"21","author":"Yamagishi","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib42","first-page":"41","article-title":"Function of insulin\u2011like growth factor 1 receptor in cancer resistance to chemotherapy (Review)","volume":"15","author":"Yuan","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.phrs.2024.107163_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fendo.2015.00059","article-title":"Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation","volume":"6","author":"Farabaugh","year":"2015","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041287","article-title":"Emerging role of IGF-1 in prostate cancer: a promising biomarker and therapeutic target","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.phrs.2024.107163_bib45","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.phrs.2024.107163_bib46","article-title":"AXL receptor in cancer metastasis and drug resistance: when normal functions go askew","volume":"13","author":"Auyez","year":"2021","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.phrs.2024.107163_bib47","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2024.107163_bib48","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2024.107163_bib50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib52","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.phrs.2024.107163_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2024.107163_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2024.107163_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.764506","article-title":"Editorial: transcriptional regulation as a key player in cancer cells drug resistance","volume":"11","author":"Martinez-Balibrea","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/metabo10070289","article-title":"Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance","volume":"10","author":"Chen","year":"2020","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib57","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.18632\/oncotarget.13907","article-title":"The role of tumor microenvironment in therapeutic resistance","volume":"8","author":"Son","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107163_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-3-16","article-title":"Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors","volume":"3","author":"Koul","year":"2004","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.phrs.2024.107163_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174236","article-title":"Genetics of ABCB1 in cancer","volume":"15","author":"Skinner","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107163_bib60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","article-title":"Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors","volume":"11","author":"Hou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2024.107163_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684098","article-title":"Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101017","article-title":"Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer","volume":"14","author":"Codony","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2024.107163_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637675","article-title":"The role of tumor-stroma interactions in drug resistance within tumor microenvironment","volume":"9","author":"Ni","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib64","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107163_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/srep20541","article-title":"Elevated expression of ABCB5 in ocular surface squamous neoplasia","volume":"6","author":"Jongkhajornpong","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098549","article-title":"CD271+ osteosarcoma cells display stem-like properties","volume":"9","author":"Tian","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.31881","article-title":"KDM5 demethylases and their role in cancer cell chemoresistance","volume":"144","author":"Plch","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.phrs.2024.107163_bib68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/atm.2016.11.82","article-title":"Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets","volume":"4","author":"Clark","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.phrs.2024.107163_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance And Their Therapeutic Implications In Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bbrc.2010.10.091","article-title":"Isolation of tumorigenic circulating melanoma cells","volume":"402","author":"Ma","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"20","key":"10.1016\/j.phrs.2024.107163_bib71","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1073\/pnas.152439599","article-title":"Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit","volume":"99","author":"Jones","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib72","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jid.2015.12.038","article-title":"ABCB5-targeted chemoresistance reversal inhibits merkel cell carcinoma growth","volume":"136","author":"Kleffel","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib73","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/cmdc.202000042","article-title":"Synthetic peroxides promote apoptosis of cancer cells by inhibiting P-glycoprotein ABCB5","volume":"15","author":"Yaremenko","year":"2020","journal-title":"ChemMedChem"},{"issue":"7176","key":"10.1016\/j.phrs.2024.107163_bib74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2024.107163_bib75","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2024.107163_bib76","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/0008-5472.CAN-03-3884","article-title":"Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance","volume":"64","author":"Huang","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2011.10.012","article-title":"CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma","volume":"315","author":"Piao","year":"2012","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib78","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.3892\/or.2014.3488","article-title":"Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K\/Akt\/p70S6K pathway in gastric cancer cells","volume":"32","author":"Zhu","year":"2014","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2024.107163_bib79","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41416-020-0885-8","article-title":"CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum","volume":"123","author":"Hsin","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CJI.0000000000000086","article-title":"Targeting CD133high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody","volume":"38","author":"Zhao","year":"2015","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib82","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2013.07.006","article-title":"Cytokine-induced killer (CIK) cells bound with anti-CD3\/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo","volume":"149","author":"Huang","year":"2013","journal-title":"Clin. Immunol. (Orlando, Fla)"},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib84","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2013.07.014","article-title":"CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer","volume":"171","author":"Swaminathan","year":"2013","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10911-012-9255-3","article-title":"A detailed mammosphere assay protocol for the quantification of breast stem cell activity","volume":"17","author":"Shaw","year":"2012","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8060165","article-title":"CD133, selectively targeting the root of cancer","volume":"8","author":"Schmohl","year":"2016","journal-title":"Toxins"},{"issue":"10","key":"10.1016\/j.phrs.2024.107163_bib87","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1535-7163.MCT-11-0206","article-title":"Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer","volume":"10","author":"Waldron","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107163_bib88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.bi.61.070192.001555","article-title":"Recombinant toxins as novel therapeutic agents","volume":"61","author":"Pastan","year":"1992","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib89","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2013.05.027","article-title":"Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression","volume":"130","author":"Skubitz","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13346-012-0066-2","article-title":"Immunotoxin targeting CD133(+) breast carcinoma cells.","volume":"3","author":"Ohlfest","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08807.x","article-title":"Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies","volume":"155","author":"Shigdar","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2012.11.032","article-title":"RNA aptamers targeting cancer stem cell marker CD133","volume":"330","author":"Shigdar","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib93","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14756366.2017.1347166","article-title":"Cancer stem cells CD133 inhibition and cytotoxicity of certain 3-phenylthiazolo[3,2-a]benzimidazoles: design, direct synthesis, crystal study and in vitro biological evaluation","volume":"32","author":"Al-Ansary","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"5119","key":"10.1016\/j.phrs.2024.107163_bib94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1126\/science.8332899","article-title":"Induction of apoptosis by the low-affinity NGF receptor","volume":"261","author":"Rabizadeh","year":"1993","journal-title":"Sci. (N. Y., NY)"},{"key":"10.1016\/j.phrs.2024.107163_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbi.2014.12.008","article-title":"N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes","volume":"234","author":"Morgan","year":"2015","journal-title":"Chem. -Biol. Interact."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib96","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers3010510","article-title":"Nerve growth factor in cancer cell death and survival","volume":"3","author":"Molloy","year":"2011","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113616","article-title":"IFT80 improves invasion ability in gastric cancer cell line via ift80\/p75NGFR\/MMP9 signaling","volume":"19","author":"Wang","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2024.107163_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092460","article-title":"Decoding the Role of CD271 in Melanoma","volume":"12","author":"Vidal","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib99","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.phrs.2024.107163_bib100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbagrm.2014.05.009","article-title":"Targeting histone lysine demethylases - progress, challenges, and the future","volume":"1839","author":"Thinnes","year":"2014","journal-title":"Biochim. Et. Biophys. Acta"},{"key":"10.1016\/j.phrs.2024.107163_bib101","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.phytochem.2015.06.028","article-title":"The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves","volume":"117","author":"Al-Qahtani","year":"2015","journal-title":"Phytochemistry"},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib102","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1159\/000430390","article-title":"Histone demethylase JMJD2A inhibition attenuates neointimal hyperplasia in the carotid arteries of balloon-injured diabetic rats via transcriptional silencing: inflammatory gene expression in vascular smooth muscle cells","volume":"37","author":"Qi","year":"2015","journal-title":"Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol., Biochem., Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib103","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1742-4658.2012.08567.x","article-title":"Studies of H3K4me3 demethylation by KDM5B\/Jarid1B\/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor","volume":"279","author":"Kristensen","year":"2012","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib104","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.chembiol.2017.02.006","article-title":"Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells","volume":"24","author":"Tumber","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nchembio.2087","article-title":"Structural analysis of human KDM5B guides histone demethylase inhibitor development","volume":"12","author":"Johansson","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib106","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.chembiol.2016.06.006","article-title":"Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds","volume":"23","author":"Horton","year":"2016","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib107","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1021\/acs.jmedchem.5b01538","article-title":"Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one derivatives","volume":"59","author":"Westaway","year":"2016","journal-title":"J. Med. Chem."},{"issue":"7520","key":"10.1016\/j.phrs.2024.107163_bib108","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature13688","article-title":"Inhibition of demethylases by GSK-J1\/J4","volume":"514","author":"Heinemann","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib109","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/acs.jmedchem.5b01635","article-title":"8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors","volume":"59","author":"Bavetsias","year":"2016","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2024.107163_bib110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchembio.2085","article-title":"An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells","volume":"12","author":"Vinogradova","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107163_bib111","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bmcl.2018.03.083","article-title":"Structure-based design and discovery of potent and selective KDM5 inhibitors","volume":"28","author":"Nie","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107163_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112161","article-title":"Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B\/JARID1B)","volume":"192","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.phrs.2024.107163_bib113","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/S0960-894X(03)00539-0","article-title":"2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase","volume":"13","author":"Mole","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.phrs.2024.107163_bib114","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1039\/c3sc51122g","article-title":"5-carboxy-8-hydroxyquinoline is a broad spectrum 2-oxoglutarate oxygenase inhibitor which causes Iron Translocation","volume":"4","author":"Hopkinson","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.phrs.2024.107163_bib115","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1556485","article-title":"KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma","volume":"2022","author":"Zhang","year":"2022","journal-title":"BioMed. Res. Int."},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133270","article-title":"Diverse functions of KDM5 in cancer: transcriptional repressor or activator?","volume":"14","author":"Ohguchi","year":"2022","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib117","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1111\/jcmm.16342","article-title":"KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3\/ITGA6 axis","volume":"25","author":"Guo","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib118","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41416-019-0680-6","article-title":"Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1","volume":"122","author":"Zhang","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2024.107163_bib119","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/0008-5472.CAN-17-1453","article-title":"A KDM5 inhibitor increases global H3K4 trimethylation occupancy and enhances the biological efficacy of 5-aza-2\u2032-deoxycytidine","volume":"78","author":"Leadem","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2024.107163_bib120","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3904645","article-title":"Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells","volume":"2019","author":"Vassalli","year":"2019","journal-title":"Stem Cells Int."},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib121","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/pr.111.005538","article-title":"Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application","volume":"64","author":"Koppaka","year":"2012","journal-title":"Pharm. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib122","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.8b00270","article-title":"DiscOVERY OF ORALLY BIOAVAILABLE, QUINOLINE-BASED ALDEHYDE Dehydrogenase 1A1 (ALDH1A1) INHIBITORS WITH POTENT CELLULAR ACtivity","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.phrs.2024.107163_bib123","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1021\/acs.jmedchem.8b00930","article-title":"Structure-based optimization of a novel class of aldehyde dehydrogenase 1A (ALDH1A) subfamily-selective inhibitors as potential adjuncts to ovarian cancer chemotherapy","volume":"61","author":"Huddle","year":"2018","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib124","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1530-0277.2009.01031.x","article-title":"Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor","volume":"33","author":"Arolfo","year":"2009","journal-title":"Alcohol., Clin. Exp. Res."},{"issue":"9","key":"10.1016\/j.phrs.2024.107163_bib125","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm.2200","article-title":"Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis","volume":"16","author":"Yao","year":"2010","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib126","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/jm401508p","article-title":"Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells","volume":"57","author":"Parajuli","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1-3","key":"10.1016\/j.phrs.2024.107163_bib127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cbi.2011.02.018","article-title":"Discovery of novel regulators of aldehyde dehydrogenase isoenzymes","volume":"191","author":"Parajuli","year":"2011","journal-title":"Chem. -Biol. Interact."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib128","first-page":"527","article-title":"alpha,beta-Acetylenic amino thiolester inhibitors of aldehyde dehydrogenases 1&3: suppressors of apoptogenic aldehyde oxidation and activators of apoptosis","volume":"20","author":"Fournet","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107163_bib129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ejmech.2007.06.004","article-title":"Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture","volume":"43","author":"Quash","year":"2008","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2024.107163_bib130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0006-2952(02)01294-7","article-title":"Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2)","volume":"64","author":"Quash","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"41","key":"10.1016\/j.phrs.2024.107163_bib131","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1038\/onc.2017.160","article-title":"ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment","volume":"36","author":"P\u00e9rez-Alea","year":"2017","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib132","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1158\/0008-5472.CAN-17-4034","article-title":"Optimized Dosing Schedule Based on Circadian Dynamics of Mouse Breast Cancer Stem Cells Improves the Antitumor Effects of Aldehyde Dehydrogenase Inhibitor","volume":"78","author":"Matsunaga","year":"2018","journal-title":"Cancer Res."},{"issue":"32","key":"10.1016\/j.phrs.2024.107163_bib133","doi-asserted-by":"crossref","first-page":"52345","DOI":"10.18632\/oncotarget.17017","article-title":"Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.phrs.2024.107163_bib134","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/jm401377v","article-title":"Development of selective inhibitors for aldehyde dehydrogenases based on substituted indole-2,3-diones","volume":"57","author":"Kimble-Hill","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107163_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111962","article-title":"Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents","volume":"187","author":"Dinavahi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242809","article-title":"Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-\u03b2-p38-ALDH2 pathway","volume":"15","author":"Yuan","year":"2020","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.phrs.2024.107163_bib137","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/jcb.30418","article-title":"ALDH2 promotes cancer stemness and metastasis in colorectal cancer through activating \u03b2-catenin signaling","volume":"124","author":"Wei","year":"2023","journal-title":"J. Cell. Biochem."},{"issue":"13","key":"10.1016\/j.phrs.2024.107163_bib138","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1038\/s41388-020-1184-9","article-title":"Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer","volume":"39","author":"Rebollido-Rios","year":"2020","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.phrs.2024.107163_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.78","article-title":"Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors","volume":"6","author":"Venton","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib140","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-018-4572-6","article-title":"ALDH1A inhibition sensitizes colon cancer cells to chemotherapy","volume":"18","author":"Kozovska","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2024.107163_bib141","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","article-title":"Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines","volume":"78","author":"Januchowski","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107163_bib142","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3892\/etm.2020.8691","article-title":"N,N-diethylaminobenzaldehyde targets aldehyde dehydrogenase to eradicate human pancreatic cancer cells","volume":"20","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"11","key":"10.1016\/j.phrs.2024.107163_bib143","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.celrep.2019.02.032","article-title":"A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells","volume":"26","author":"Chefetz","year":"2019","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.phrs.2024.107163_bib144","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/en.2019-00362","article-title":"Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture","volume":"160","author":"Shiba","year":"2019","journal-title":"Endocrinology"},{"issue":"50","key":"10.1016\/j.phrs.2024.107163_bib145","doi-asserted-by":"crossref","first-page":"43486","DOI":"10.1074\/jbc.M111.293597","article-title":"Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases","volume":"286","author":"Khanna","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107163_bib146","article-title":"Identification of intrinsic drug resistance and its biomarkers in high-throughput pharmacogenomic and CRISPR screens","volume":"1","author":"Ayestaran","year":"2020","journal-title":"Patterns (N. Y., NY)"},{"key":"10.1016\/j.phrs.2024.107163_bib147","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","article-title":"Epigenetic therapeutics: a new weapon in the war against cancer","volume":"67","author":"Ahuja","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.phrs.2024.107163_bib148","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jid.2016.08.033","article-title":"Preclinical advances with multiphoton microscopy in live imaging of skin cancers","volume":"137","author":"Sun","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"17","key":"10.1016\/j.phrs.2024.107163_bib149","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2174\/156802610792928077","article-title":"PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel","volume":"10","author":"Kurdziel","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107163_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1301649","article-title":"Assessment of chemotherapy resistance changes in human colorectal cancer xenografts in rats based on MRI histogram features","volume":"14","author":"Wu","year":"2024","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107163_bib151","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model","volume":"18","author":"Moghal","year":"2023","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.phrs.2024.107163_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1086097","article-title":"Deep learning methods for drug response prediction in cancer: predominant and emerging trends","volume":"10","author":"Partin","year":"2023","journal-title":"Front. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T03:36:11Z","timestamp":1714275371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824001075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":152,"alternative-id":["S1043661824001075"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107163","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological agents targeting drug-tolerant persister cells in cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107163"}}